Literature DB >> 22538516

EBV-positive diffuse large B-cell lymphoma of the elderly is an aggressive post-germinal center B-cell neoplasm characterized by prominent nuclear factor-kB activation.

Santiago Montes-Moreno1, Lina Odqvist, Julio A Diaz-Perez, Ana Batlle Lopez, Sonia Gonzalez de Villambrosía, Francisco Mazorra, Maria E Castillo, Mar Lopez, Raquel Pajares, Juan F García, Manuela Mollejo, Francisca I Camacho, Carmen Ruiz-Marcellán, Magdalena Adrados, Nazario Ortiz, Renato Franco, Carlos Ortiz-Hidalgo, Ana Suarez-Gauthier, Ken H Young, Miguel A Piris.   

Abstract

Here, we report a retrospective series of 47 EBV-positive diffuse large B-cell lymphoma associated with advanced age. Histopathology allowed to the identification of different histological patterns: cases with polymorphic diffuse large B-cell lymphoma (29 cases), Hodgkin-like (8 cases) and polymorphic lymphoproliferative disorder-like (9 cases) patterns. One case was purely monomorphic diffuse large B-cell lymphoma. We show that this lymphoma type is a neoplasm with prominent classical and alternative nuclear factor-kB pathway activation in neoplastic cells (79% of the cases showed nuclear staining for p105/p50, 74% for p100/p52 and 63% for both proteins), with higher frequency than that observed in a control series of EBV-negative diffuse large B-cell lymphoma (χ(2) <0.001). Most cases showed an activated phenotype (95% non-germinal center (Hans algorithm); 78% activated B cell (Choi algorithm)). Clonality testing demonstrated IgH and/or K/Kde/L monoclonal rearrangements in 64% of cases and clonal T-cell populations in 24% of cases. C-MYC (1 case), BCL6 (2 cases) or IgH (3 cases) translocations were detected by FISH in 18% cases. These tumors had a poor overall survival and progression-free survival (the estimated 2-year overall survival was 40 ± 10% and the estimated 2-year progression-free survival was 36 ± 9%). Thus, alternative therapies, based on the tumor biology, need to be tested in patients with EBV-positive diffuse large B-cell lymphoma of the elderly.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22538516     DOI: 10.1038/modpathol.2012.52

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  57 in total

Review 1.  Epstein-Barr Virus-associated lymphoproliferative disorders: experimental and clinical developments.

Authors:  Lingyun Geng; Xin Wang
Journal:  Int J Clin Exp Med       Date:  2015-09-15

Review 2.  The biology of aging and lymphoma: a complex interplay.

Authors:  Clémentine Sarkozy; Gilles Salles; Claire Falandry
Journal:  Curr Oncol Rep       Date:  2015-07       Impact factor: 5.075

Review 3.  NF-κB signaling pathway and its potential as a target for therapy in lymphoid neoplasms.

Authors:  Li Yu; Ling Li; L Jeffrey Medeiros; Ken H Young
Journal:  Blood Rev       Date:  2016-10-13       Impact factor: 8.250

4.  EBV-positive large B-cell lymphomas in young patients: a nodal lymphoma with evidence for a tolerogenic immune environment.

Authors:  Alina Nicolae; Stefania Pittaluga; Shahed Abdullah; Seth M Steinberg; Thu Anh Pham; Theresa Davies-Hill; Liqiang Xi; Mark Raffeld; Elaine S Jaffe
Journal:  Blood       Date:  2015-05-21       Impact factor: 22.113

5.  Epstein-Barr virus-positive follicular lymphoma.

Authors:  Nicholas Mackrides; German Campuzano-Zuluaga; Yvan Maque-Acosta; Adrienne Moul; Nouf Hijazi; Francis Offiong Ikpatt; Ronald Levy; Ramiro E Verdun; Kranthi Kunkalla; Yasodha Natkunam; Izidore S Lossos; Francisco Vega; Jennifer Chapman
Journal:  Mod Pathol       Date:  2016-12-16       Impact factor: 7.842

6.  Clinicopathologic correlates of MYD88 L265P mutation and programmed cell death (PD-1) pathway in primary central nervous system lymphoma.

Authors:  Tarsheen K Sethi; Alexandra E Kovach; Natalie S Grover; Li-Ching Huang; Laura A Lee; Samuel M Rubinstein; Yang Wang; David S Morgan; John P Greer; Steven I Park; Mary Ann Thompson-Arildsen; Ashwini Yenamandra; Cindy L Vnencak-Jones; Nishitha M Reddy
Journal:  Leuk Lymphoma       Date:  2019-06-11

7.  Clinicopathologic consensus study of gray zone lymphoma with features intermediate between DLBCL and classical HL.

Authors:  Monika Pilichowska; Stefania Pittaluga; Judith A Ferry; Jessica Hemminger; Hong Chang; Jennifer A Kanakry; Laurie H Sehn; Tatyana Feldman; Jeremy S Abramson; Athena Kritharis; Francisco J Hernandez-Ilizaliturri; Izidore S Lossos; Oliver W Press; Timothy S Fenske; Jonathan W Friedberg; Julie M Vose; Kristie A Blum; Deepa Jagadeesh; Bruce Woda; Gaurav K Gupta; Randy D Gascoyne; Elaine S Jaffe; Andrew M Evens
Journal:  Blood Adv       Date:  2017-12-11

8.  Prevalence and clinical implications of epstein-barr virus infection in de novo diffuse large B-cell lymphoma in Western countries.

Authors:  Chi Young Ok; Ling Li; Zijun Y Xu-Monette; Carlo Visco; Alexander Tzankov; Ganiraju C Manyam; Santiago Montes-Moreno; Karen Dybkaer; Karen Dybaer; April Chiu; Attilio Orazi; Youli Zu; Govind Bhagat; Jiayu Chen; Kristy L Richards; Eric D Hsi; William W L Choi; J Han van Krieken; Jooryung Huh; Weiyun Ai; Maurilio Ponzoni; Andrés J M Ferreri; John P Farnen; Michael B Møller; Carlo E Bueso-Ramos; Roberto N Miranda; Jane N Winter; Miguel A Piris; L Jeffrey Medeiros; Ken H Young
Journal:  Clin Cancer Res       Date:  2014-02-28       Impact factor: 12.531

Review 9.  Aggressive B-cell lymphomas: how many categories do we need?

Authors:  Jonathan W Said
Journal:  Mod Pathol       Date:  2012-11-16       Impact factor: 7.842

10.  CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study.

Authors:  Shimin Hu; Zijun Y Xu-Monette; Aarthi Balasubramanyam; Ganiraju C Manyam; Carlo Visco; Alexander Tzankov; Wei-min Liu; Roberto N Miranda; Li Zhang; Santiago Montes-Moreno; Karen Dybkær; April Chiu; Attilio Orazi; Youli Zu; Govind Bhagat; Kristy L Richards; Eric D Hsi; William W L Choi; J Han van Krieken; Qin Huang; Jooryung Huh; Weiyun Ai; Maurilio Ponzoni; Andrés J M Ferreri; Xiaoying Zhao; Jane N Winter; Mingzhi Zhang; Ling Li; Michael B Møller; Miguel A Piris; Yong Li; Ronald S Go; Lin Wu; L Jeffrey Medeiros; Ken H Young
Journal:  Blood       Date:  2013-01-23       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.